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Abstract. Key-press responding of mice was maintained 
under a fixed-ratio (FR) 30-response schedule of  food pre- 
sentation. Successive 3-rain periods during which the experi- 
mental chamber was illuminated and the schedule was in 
effect were preceded by 10-rain time-out (TO) periods dur- 
ing which all lights were out and responses had no sched- 
uled consequences. Intraperitoneal (IP) injections of  saline 
or of cumulative doses of drugs were given at the start 
of each TO period. Successive saline injections had little 
or no effect on response rates, whereas the/z-opioid agonists 
morphine (0.1-10.0 mg/kg) and levorphanol (0.1 3.0 mg/ 
kg), the ~c-opioid agonist ethylketazocine (0.03-3.0 mg/kg), 
the mixed/~-/6-opioid agonist metkephamid (0.1-10.0 rag/ 
kg), and the nonopioid dissociative anesthetic ketamine 
(1.0-100.0mg/kg) generally produced dose-related de- 
creases in response rates. Following chronic administration 
of morphine (100.0 mg/kg/6 h), tolerance developed to the 
effects of morphine on rates of responding. In addition, 
a comparable degree of cross-tolerance developed to the 
effects of levorphanol and metkephamid. On the other 
hand, there was no evidence of cross-tolerance to the effects 
of ethylketazocine or ketamine. These results are consistent 
with the evidence suggesting that different opioid agonists 
exert their behavioral effects through distinct classes of 
opioid receptors. 
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One characteristic observation with repeated administration 
of opioids is the development of tolerance to many of their 
effects. The tolerance that develops to opioid effects may 
derive from a specific decrease in the density of opioid re- 
ceptors (e.g., Davis et al. 1979; however, see Law et al. 
1984). Thus, the display of cross-tolerance between different 
opioids might indicate commonalities in their mechanisms 
Present addresses: 
* Department of Pharmacology, University of Iowa College of 
Medicine, Iowa City, IA 52242, USA 
** CNS Drug Discovery Program, Warner-Lambert/Parke-Davis 
Pharmaceutical Research Divisaon, Ann Arbor, MI 48105, USA 
*** National Institute on Drug Abuse, Addiction Research Center, 
P.O. Box 5180, Baltimore, MD 21224, USA 
Offprint requests to: J.L. Katz 
of action (e.g., that they are agonists at the same opioid 
receptor type). For example, Schulz and Wuster (1981) 
chronically treated mice with either the /z agonist sufen- 
tanyl, several x agonists, or the g agonist [D-Ala2,D-LeuS]en- 
kephalin (DADL), and subsequently studied the response 
to opioids of the electrically-driven vas deferens of these 
subjects. Subjects treated with sufentanyl developed toler- 
ance to the effects of the drug; however, cross-tolerance 
was not conferred to the x or J agonists. In general, similar 
effects were observed with tolerance to the other com- 
pounds; though cross tolerance to the tc agonists did not 
confer to other Jc agonists the same degree of cross toler- 
ance. The authors suggested that subtypes of/ t  and ~c recep- 
tors may account for the different degrees of cross-tolerance 
conferred. Selective tolerance between/~ and J agonists has 
also been observed in vivo for some behavioral effects of 
sufentanyl and DADL (Schulz et al. 1981). 
The purpose of the present study was to evaluate the 
specificity of tolerance to effects of morphine on schedule- 
controlled behavior in mice. To this end, tolerance was pro- 
duced to the effects of morphine, and cross-tolerance was 
assessed to other opioid agonists and to the non-opioid 
agonist ketamine. Opioid agonists studied in addition to 
morphine were the /l agonist levorphanol, the ~c agohist 
ethylketazocine and the #/O agonist metkephamid. Metke- 
phamid was of particular interest, as there are inconsisten- 
cies with regard to whether morphine confers cross-toler- 
ance to this drug. For example, initial studies of analgesic 
effects in mice indicated no cross-tolerance conferred to 
metkephamid with morphine treatment (Frederickson et al. 
1981; Hynes et al. 1982). Similarly, Locke and Holtzman 
(1986) reported no cross-tolerance to metkephamid with 
morphine treatment on locomotor activity. Others, how- 
ever, have reported cross-tolerance to the effects of mor- 
phine and metkepharnid on operant behavior in pigeons 
(Leander and Wood 1982) and analgesic effects in mice 
(Leander 1987). Thus, determinants of whether cross-toler- 
ance is observed may be related to the effect being studied. 
Further, with mice there is inconsistent data with regard 
to whether cross-tolerance to metkephamid is conferred by 
morphine treatment. 
Methods 
Subjects. Three adult male Swiss-Webster mice originally 
weighing 30.0-37.5 g were used. Subjects were housed indi- 
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vidually and had unrestricted access to water in theft home 
cages. Body weights were maintained at 80% of the unre- 
stricted feeding weights by adjusting the daily rations of 
food pellets (P.J. Noyes, Lancaster, NH) that supplemented 
milk obtained during experimental sessions. The daily or 
weekend ration of pellets was given to subjects after ses- 
sions. The subjects were experimentally naive at the start 
of the experiment. 
Apparatus. During experimental sessions the mice were 
placed in a chamber described previously (Katz 1984) which 
was placed in a ventilated, sound-attenuating aluminum 
shell. A small aluminum-floored corridor at the front of 
the chamber had a small-rodent response paddle (BRS/ 
LVE, Beltsville, MD, # RLP-003) at one end. Depression 
of the paddle with a force exceeding 2 g (0.02 N) produced 
a click of a relay mounted outside the chamber and was 
recorded as a response. Overhead illumination, provided 
by a white lamp (7.5 W, 120 V, a.c.) served as a visual 
stimulus. White noise, provided by a speaker mounted on 
the back wall of the chamber, served as an auditory stimu- 
lus. A solenoid-operated dipper (R. Gebrands Co., Arl- 
ington, MA, modified Model B-LH) delivered 0.025 mi of 
evaporated milk through a hole in the floor of the corridor 
in front of the response paddle. 
Procedure. Mice were trained to depress the response paddle 
during experimental sessions that were conducted five days 
per week. Sessions began with a 10-rain timeout (TO) period 
during which the white noise and the overhead illumination 
were off and responses had no scheduled consequences. The 
TO was followed by a 3-rain period during which the white 
noise and overhead illumination were on and responses pro- 
duced milk according to a fixed-ratio (FR) schedule. Under 
the FR schedule each 30th response produced access to 
evaporated milk via the dipper that was accessible for 3 s. 
Sessions were comprised of five TO periods, each followed 
by a 3-min period of FR reinforcement. 
Once performances were stable on a day-to-day basis 
(no increasing or decreasing trends in response rates), sub- 
jects were adapted to within-session saline injections. Dur- 
ing selected sessions two or three times per week, saline 
injections were administered IP at the start of each TO 
period. When injection and handling of the subject no lon- 
ger disrupted the behavioral performance, effects of drugs 
were assessed. Before selected sessions, and no more fre- 
quently than once per week with opioids or once every 
3 days for ketamine (typically Tuesdays and Fridays), drugs 
were administered in increasing cumulative doses at the 
start of each timeout period. Each successive injection was 
of an amount of drug that incremented the total dose in- 
jected within that session by one-half log unit. 
Once dose-effect curves for each of the drugs were deter- 
mined, subjects were rendered tolerant to effects of mor- 
phine by administering the drug every 6 h. During the 1st 
week of chronic morphine, injections of 30.0 mg/kg were 
given at 01:00, 07:00, 13:00 and 19:00 hours. Fo l lo~ng  
the 1st week, the dose was increased to 100.0 mg/kg/6 h. 
During the morphine treatment regimen, experimental ses- 
sions were conducted from 2 to 4 h  following the 
07:00 hour morphine injection, the time of day at which 
sessions were conducted before chronic morphine treat- 
ment. Subjects were readapted to the injection procedure 
with saline injections and were then tested again with the 
various drugs studied prior to the induction of morphine 
tolerance. 
Analysis of results. Response rates were calculated by divid- 
ing total responses by elapsed time during the fixed-ratio 
component for individual subjects. Response rates were 
transformed to a percentage of rates occurring during the 
corresponding component during vehicle control sessions. 
Percentage of control data on the linear portions of the 
dose-effect curves were analyzed by standard parallel line 
bioassay techniques (Finney 1964) to obtain potency esti- 
mates. Analysis of variance and linear regression techniques 
(Snedecor and Cochran 1967) were used to determine ED~o 
values (the dose causing a decrease in response rates to 
50% of the control rate) and 95% confidence limits. 
Drugs. Morphine sulfate (NIDA), ethylketazocine methane- 
sulfonate (Sterling-Winthrop, Rensselaer, NY), levor- 
phanol tartrate (Hoffmann-La Roche, Nutley, NJ), keta- 
mine hydrochloride (Warner-Lambert, Ann Arbor, MI) 
and metkephamid (Try-D-Ala-Gly-Phe-N(Me)Met-amide; 
Eli Lilly, Indianapolis, IN) were dissolved in sterile saline 
(0.9% NaC1) or distilled water for injection. All drugs were 
administered intraperitoneally (IP). Doses are expressed as 
the above forms of the drugs in mg per kg body weight 
of the subject. 
Results 
In the absence of injections, responding of mice under the 
FR 30 schedule was similar to that typically seen with this 
type of schedule (Ferster and Skinner 1957). At the onset 
of each component there was a brief pause that was fol- 
lowed by an abrupt transition to responding at a high rate 
that was maintained until milk presentation. Little or no 
responding occurred during the TO periods. When saline 
injections were administered prior to each component of 
the daily sessions, the rates of responding were similar ac- 
ross the successive components before and during chronic 
morphine administration (Fig. 1, panel A). Repeated mea- 
sures analysis of variance of data collected after saline injec- 
tions showed no significant difference in response rates with 
repeated injections [F(4,16 = 1.23], before or during chronic 
morphine [F(4,16 = 1.00], or an interaction [F(4,16 = 0.343]. 
Before its chronic administration, morphine produced 
dose-related decreases in rates of responding (Fig. 1, pan- 
el B, Filled points). The EDso value was 2.9 mg/kg (Table 1), 
and responding was virtually eliminated at 10.0 mg/kg. 
After chronic administration of morphine, the drug contin- 
ued to produce dose-related decreases in response rates 
(Fig. 1, panel B, unfilled points), but the dose-effect curve 
was shifted approximately one log unit to the right (the 
relative potency ratio for morphine was 0.11, Table 1). The 
ED~o value was increased to 27.5 mg/kg (Table 1), and re- 
sponding was not eliminated up to a dose of 100.0 mg/kg. 
Both levorphanol and metkephamid produced patterns 
of effects similar to that of morphine (Fig. 1, panels C and 
D). Dose-related decreases in response rates were observed 
with both drugs, prior to as well as following chronic mor- 
phine treatment. The ED~o value of levorphanol was in- 
creased from 1.3 to 14.2. For both drugs, the dose-effect 
curves were shifted approximately 1 log unit to the right 
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Fig. 1. Effects of saline or cumulative doses of drugs on average rates of responding of mice studied under the FR 30 TO 10-min 
schedule of milk presentation, prior to and following the development of morphine tolerance. Upper left panel ordinates, response 
rate in responses per s. Upper left panel abscissae: Successwe components. Other ordinates: response rates as a percentage of control 
(saline) rates. Other abscissae: cumulative doses of drugs in mg/kg on logarithmic scales. For each dose of drug, response rates are 
expressed as a percentage of the average control rates in the corresponding component; for the two highest doses of metkephamid, 
the average response rates over the entire sessions were used as the control, since a corresponding rate for saline was not available. 
Filled points show the effects of saline injections or drugs prior to chronic morphine treatment; anfilledpoints show effects after chronic 
morphine treatment 
Table 1. Summary of effective doses and relative potencies of com- 
pounds before and during the repeated administration of morphine 
Drug EDso Value 
Before During Relative potency 
Morphine 2.9 27.5 0.11 
(1.6-5.2) (15.648.3) (0.054).21) 
Ethylketazocine 1.7 0.5 2.10 
(0.%2.5) (0.4-0.7) (0.83~.49) 
Levorphanol 1.3 14.2 0.11 
(0.9-1.9) (5.0M.0.6) (0.05q3.25) 
Metkephamid 2.8 NS 0.10 
(1.6-4.8) (0.02~).43) 
Ketamine 57.6 NS 1.38 
(10.0-331.6) (0.32 17.92) 
Values for ED~o are expressed in mg/kg for data collected before 
and during the repeated administration of morphine (100 mg/kg/ 
6 h). The values for relative potency represent the dose of the drug, 
in mg/kg, "before" treatment, equal to 1 mg/kg of the drug "dur- 
ing" treatment. All numbers within parentheses are the 95% confi- 
dence limits. Invalid bioassays (NS) were caused by a lack of signif- 
icance in the linear regression analysis 
relative potency ratios for levorphanol and metkephamid 
were 0.11 and 0.10, respectively, Table 1). 
As with the other opioids, ethylketazocine generally pro- 
duced dose-related decreases in response rates before chron- 
ic administration of morphine (Fig. 1, panel E, f'tlled points) 
with an EDso value of 1.7 mg/kg (Table 1). In contrast to 
the results observed with the other agonists, the dose-effect 
curve for the effects of ethylketazocine was not shifted to 
the right with chronic morphine treatment (Fig. 1, panel E, 
unfilled points). Rather, the EDso value was decreased to 
0.5 mg/kg and the relative potency estimate was 2.1 (Ta- 
ble 1). 
Ketamine produced small increases in response rates 
at the lesser doses (1.0-10.0 mg/kg), and dose-related de- 
creases in response rates at greater doses (30.0-100.0 rag/ 
kg) prior to chronic morphine treatment (Fig. 1, panel F, 
filled points). After chronic administration of morphine, 
the lesser doses of ketamine no longer increased response 
rates, and the doses of ketamine that decreased rates of 
responding were the same doses that had done so prior 
to chronic morphine treatment (Fig. 1, panel F, unfilled 
points). The E D i t  value for the linear portion of the dose- 
effect curve before chronic treatment was 57.6 mg/kg, with 
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a relative potency ratio of 1.38, indicating no significant 
change in potency due to morphine treatment. 
Discussion 
Key-press responding of mice was maintained by milk rein- 
forcement under an FR 30 schedule in which successive 
components of the session were preceded by injections of 
saline or drugs. The multiple saline injections had little or 
no effect on response rates across the session, and, as has 
been found previously (e.g., Young 1986; Solomon et al. 
1987), the effects of cumulative doses were similar to the 
effects of single doses. Further, the effects of each of the 
drugs studied were similar to effects previously reported 
for these compounds (e.g., McMillan et al. 1970; Thomp- 
son et al. 1970; Solomon et al. 1982). These results indicate 
that the procedure is appropriate for evaluation of the ef- 
fects of cumulative doses of drugs. 
Following chronic treatment with morphine, cross-toler- 
ance was found to have developed to the #-opioid agonist 
levorphanol. The degree of shift in the dose-response func- 
tion for levorphanol was comparable to that seen with mor- 
phine, which agrees with earlier results obtained with levor- 
phanol or with the/x-opioid agonist levomethorphan in pi- 
geons and monkeys (Woods and Carney 1978). This result 
suggests that the display of cross-tolerance to effects of 
opioids on operant behavior may be dependent on com- 
monalities in their mechanisms of action (e.g., that they 
act at the same opioid receptor subtype). However, a similar 
degree of cross-tolerance was seen between morphine and 
the mixed #-/6-opioid agonist metkephamid. In a previous 
report of the effects of metkephamid on operant behavior 
in pigeons (Leander and Wood 1982), a more limited degree 
of cross-tolerance between metkephamid and the #-opioid 
agonist methadone was found, and in other studies that 
examined behavioral or other effects (e.g., antinociception) 
of these agents, an absence of cross-tolerance between mor- 
phine and metkephamid was seen (e.g., Locke and Holt.z- 
man 1986; Hynes and Fredrickson 1982). Thus, while met- 
kephamid is considered to possess equal affinity with mor- 
phine for the #-opioid receptor and a greater affinity than 
morphine for the 6-opioid receptor (Burkhardt et al. 1981), 
the present finding of cross-tolerance between morphine 
and metkephamid, along with the report of Leander and 
Wood (1982), suggest that #-opioid receptors may be the 
primary site of action for the effects of metkephamid on 
operant behavior. In contrast, its action at fi-opioid recep- 
tors may be more important for its analgesic effects (Burk- 
hardt et al. 1982; however see Leander 1987). 
The absence of morphine-induced cross-tolerance to 
ethylketazocine is consistent with the theory that these 
agents act at distinct subtypes of opioid receptors. The pos- 
sible development of sensitization to the effects of ethylketa- 
zocine, however, is more difficult to account for. One group 
of agents that show sensitization to their effects following 
chronic treatment with morphine are the opioid antagonists 
(e.g., Valentino et al. 1983). However, an opioid-antagonist 
action of ethylketazocine is not likely, since this drug fails 
to precipitate opioid withdrawal in morphine-dependent 
rhesus monkeys (e.g., Swain and Seevers 1974; see also 
Woods et al. 1979), and chronic administration of ethylke- 
tazocine itseff also produces an increased sensitivity to the 
behavioral effects of opioid antagonists, although to a lesser 
degree than does morphine (e.g., Tepper and Woods 1978). 
The dose-response function for the respouse-rate de- 
creasing effects of the non-opioid dissociative anesthetic ke- 
tamine was generally unaffected by chronic morphine treat- 
ment. Ketamine and its structural analog phencycfidine 
share many pharmacological effects with the a-opioid ago- 
nist N-allylnormetazocine (e.g., Solomon et al. 1981). The 
present observation of a lack of cross-tolerance between 
morphine and ketamine suggests that ketamine, and per- 
haps other ~-opioid agonists as well, do not share important 
mechanisms of action with/~-opioids, such as morphine. 
In conclusion, the results of this study demonstrate that 
the development of tolerance to morphine is accompanied 
by a selective pattern of cross-tolerance to other opioid 
agonists. A substantial degree of cross-tolerance was found 
between morphine and agonists that also act at/l-opioid 
receptors, either exclusively (e.g., levorphanol) or in part 
(e.g., metkephamid). In contrast, there was no cross-toler- 
ance to the K-opioid agonist ethylketazocine, nor to the 
dissociative anesthetic ketamine. These results are consis- 
tent with the theory that action at a number of receptor 
subtypes can account for the variety of effects produced 
by different opioid agonists, and suggest that studies on 
cross-tolerance may be useful to classify opioids with regard 
to their mechanisms of action on operant behavior. 
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